13:53 ET -- Moderna Inc. is one of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The pharmaceutical company said Thursday that supply constraints for its Covid-19 vaccines could reduce 2022 sales by up to $3 billion. Overall for the third quarter, Moderna said its net income fell to $1 billion, or $2.53 a share, compared with $3.3 billion, or $7.70 a share, a year earlier. The company said its R&D costs rose 57% in the quarter, but the results of various experimental vaccine studies are due out in the coming weeks and months. Moderna shares were down 1.9% at $145.74 at 13:53 ET. Dow Jones & Co. owns Factiva. (susan.solan@wsj.com)

(END) Dow Jones Newswires

November 03, 2022 14:08 ET (18:08 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Moderna Charts.